Jubilant Life May BuyBack Eli Lilly's Stake In Drug Discovery JV
by Irfan Khan
Jubilant Life Sciences may buyback Eli Lilly & Company's stake in their drug discovery JV - Vanthys Pharmaceuticals as both the partners have decided to calloff the partnership. According to ET, Jubilant will absorb the two dozen-odd employees, mostly scientists working at the centre.
Bangalore based Vanthys Pharmaceuticals was formed in 2008 as a 50:50 JV between the two to develop molecules from the pre-clinical to phase II stage across oncology, diabetes and cardiovascular segments.
At the time of the announcement, the two firms had said they would jointly invest $8Mn in the Bangalore-based firm over the next three years.
Initially, Jubilant Life Sciences and Eli Lilly had begun work on about a dozen molecules, transferred from their respective research portfolio into the JV. The two companies will retain intellectual property of their respective molecules.
Cremica Food Industries is planning to tap the PE players to raise close to R150 Cr giving away a minority stake in the company for financing its expansion plans. Cremica is said to be in talks with PE funds including Tata Capital and is seeking a valuation of over R800 Cr.